-
Beyond the Growth Chart: New Long-Term Data on VOXZOGO® for Achondroplasia
NASDAQ: $BMRN The landscape of pediatric endocrinology is shifting. At the Pediatric Endocrine Society’s (PES) 2026 Annual Meeting in San Francisco, new data presented by BioMarin Pharmaceutical Inc. has provided a clearer picture of how long-term treatment with VOXZOGO® (vosoritide) impacts children with achondroplasia. While height is often the most visible metric in skeletal dysplasias,…
-
New Two-Year Data on CRENESSITY® (crinecerfont) Shows Lasting Health Benefits for Children with Classic Congenital Adrenal Hyperplasia
NASDAQ: $NBIX Recent findings presented at the Pediatric Endocrine Society 2026 Annual Meeting offer a promising outlook for the pediatric community living with classic congenital adrenal hyperplasia (CAH). Neurocrine Biosciences has released new two-year data from the Phase 3 CAHtalyst® Pediatric study, revealing that long-term treatment with CRENESSITY® (crinecerfont) provides durable hormone control and allows…
-
Viatris Advances Contraceptive Care: New Data on Weekly Low-Dose Patch to be Presented at ACOG 2026
NASDAQ: $VTRS As we approach the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting in Washington, D.C., the medical community is turning its attention toward significant advancements in reproductive health. Viatris Inc. recently announced it will present six new abstracts regarding its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly…
-
Kodiak Sciences Advances Pipeline and Unveils New Clinical Data for KSI-101 in Uveitis Treatment
NASDAQ: $KOD Kodiak Sciences Inc. has announced significant progress in its clinical and scientific programs, with plans to present new data at the 2026 American Uveitis Society (AUS) Meeting and the Association for Research in Vision and Ophthalmology (ARVO) Meeting. These updates center on the clinical performance of KSI-101 in treating macular edema secondary to…
-
Insmed Sets Sights on May 2026: What Investors Should Watch
NASDAQ: $INSM Insmed Incorporated has officially announced its participation in a series of upcoming investor conferences throughout May 2026. This move signals a proactive effort by the biopharmaceutical company to maintain transparency and provide clarity regarding its ongoing clinical pipeline and commercial strategies. Why These Appearances Matter Investor conferences serve as a critical bridge between…
-
10x Genomics Scheduled to Present at 46th Annual TD Cowen Health Care Conference
NASDAQ: $TXG 10x Genomics, Inc., a prominent innovator in the fields of single cell and spatial biology, has confirmed its participation in a significant industry event next month. The company announced that key members of its management team are slated to present at the highly anticipated 46th Annual TD Cowen Health Care Conference. The scheduled…
-
Compugen Set to Present at Key Investor Conferences in Early 2026
NASDAQ: $CGEN Compugen Ltd., a clinical-stage company pioneering cancer immunotherapy through advanced AI/ML-powered computational drug target discovery, has announced its management team will be participating in two significant investor conferences in the coming months. These appearances offer an important opportunity for stakeholders to gain insight into the company’s progress across its differentiated pipeline. The first…
-
QuidelOrtho Announces Presentation at Prestigious Raymond James 47th Annual Institutional Investor Conference
NASDAQ: $QDEL QuidelOrtho Corporation, a recognized global leader in innovative in vitro diagnostics, has officially announced its participation in a significant industry event: the Raymond James 47th Annual Institutional Investor Conference. This presentation offers a valuable opportunity for investors, analysts, and industry stakeholders to gain direct insight into the company’s strategic direction, recent performance, and…
-
Decoy Therapeutics Highlights Global Access Commitment Following Investor Presentation
NASDAQ: $DCOY Decoy Therapeutics Showcases Commitment to Global Accessibility During Recent Investor Event Decoy Therapeutics, Inc. recently participated in a dedicated segment during a virtual investor conference, focusing a significant portion of its presentation on the implications and execution strategy of its recently announced Global Access Commitment Agreement. The company utilized this platform to elaborate…
-
Legend Biotech Announces Key Data Presentation for CARVYKTI at 2026 Tandem Meetings
NASDAQ: $LEGN Advancing the Frontier: Legend Biotech Prepares for Major Data Showcase Legend Biotech Corporation (NASDAQ: $LEGN) has recently announced an important upcoming event that underscores their commitment to innovative cancer therapies. According to a press release dated January 21, 2026, the company will be presenting new data concerning its groundbreaking therapy, CARVYKTI® (ciltacabtagene autoleucel),…
-
Orphai Therapeutics’ LAM-001 Study Chosen for Key Presentation at ATS 2026
Orphai Therapeutics has achieved a significant milestone this week with the announcement that their Phase 2a clinical trial data for LAM-001 will be presented orally at the prestigious American Thoracic Society (ATS) 2026 International Conference. This selection is a strong indicator of the potential importance of their findings within the respiratory medicine community. Understanding the…
-
Clene’s Upcoming Presentation at the Emerging Growth Conference: What Investors Should Know
NASDAQ: $CLNN Clene Inc., a clinical-stage company focused on developing treatments that target neurodegeneration and inflammation, has announced its participation in a significant industry event. The company is scheduled to present at the Emerging Growth Conference, as detailed in their recent press release. The Significance of the Emerging Growth Conference The Emerging Growth Conference (EGC)…
-
Abpro’s ABP-102 Takes Center Stage at J.P. Morgan Healthcare Conference via Celltrion Presentation
NASDAQ: $ABP The recent announcement surrounding Abpro Therapeutics’ lead product candidate, ABP-102, has generated considerable excitement within the biotechnology sector. According to a press release published on GlobeNewswire, details regarding this promising program were prominently featured during a presentation by Celltrion Healthcare Co., Ltd. at the prestigious 44th Annual J.P. Morgan Healthcare Conference. For those…
-
Ascentage Pharma Shares Vision for Global Expansion at J.P. Morgan Conference
NASDAQ: $AAPG The recent 44th Annual J.P. Morgan Healthcare Conference served as a pivotal stage for Ascentage Pharma to articulate its comprehensive strategy for worldwide growth and innovation. The company, a dynamic force in the biopharmaceutical sector, used its presentation slot to detail how it plans to propel its pipeline from clinical promise to global…
-
Centessa Pharmaceuticals Expands Orexin Receptor Pipeline into Neuropsychiatric Territory
NASDAQ: $CNTA Centessa Pharmaceuticals recently made a significant announcement regarding the expansion of its pipeline, specifically leveraging its Orexin Receptor 2 (OX2R) agonist program. A press release detailed plans for a poster presentation at an upcoming scientific meeting, showcasing new preclinical data that supports moving these compounds into development for neuropsychiatric indications. For those unfamiliar,…
-
Decoding the Future of Rare Disease Treatment: Travere Therapeutics at J.P. Morgan Healthcare Conference 2026
NASDAQ: $TVTX The Annual Gathering of Titans: Why J.P. Morgan Matters Every January, the city of San Francisco transforms into the epicenter of the global life sciences industry. The J.P. Morgan Healthcare Conference (JPM) is more than just a series of presentations; it’s where deals are forged, strategies are unveiled, and the trajectory of pharmaceutical…
-
Clover Health to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
NASDAQ: $CLOV Clover Health’s upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference holds significant promise for the healthcare industry and market observers alike. As a key player in the healthcare sector, Clover Health’s involvement in this prestigious event underscores its commitment to innovation, growth, and industry leadership. This article delves into the details…
-
Presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial highlighting new findings from the ATTENTION-AD study evaluating potential benefit of oral once daily blarcamesine (ANAVEX®2-73) in early Alzheimer’s disease.
NASDAQ: $AVXL The presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial marks a significant milestone in the field of Alzheimer’s disease research. This article delves into the latest findings from the ATTENTION-AD trial, shedding light on the efficacy and safety of the investigational treatment over an extended period. With a…
-
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR?-targeted ADC, on January 4, 2024
NASDAQ: $STRO 1. Introduction to Sutro Biopharma’s Investor Webcast Welcome to the article covering the upcoming investor webcast hosted by Sutro Biopharma on January 4, 2024. This webcast aims to highlight the potential multi-cancer opportunity associated with Luvelta, a promising FolR?-targeted Antibody-Drug Conjugate (ADC) developed by Sutro Biopharma. In this article, we will delve into…
-
Actinium | Highlights Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
NYSE: $ATNM NEW YORK, Dec. 8, 2023 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: $ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that clinical data from its Iomab-B and Actimab-A programs will be featured in four presentations at the 65th Annual American Society of Hematology Annual Meeting &…
-
Curis Announces Three Presentations at ASH
NASDAQ: $CRIS LEXINGTON, Mass., Dec. 6, 2023 /PRNewswire/ — Curis, Inc. (NASDAQ: $CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company along with its collaborative partners will be presenting three posters at the upcoming 65th ASH Annual Meeting and Exposition (ASH…
-
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer’s
NASDAQ: $SNPX 1. Introduction: Synaptogenix’s participation in USC-Sponsored Forum on Age-Related Diseases Synaptogenix, a renowned leader in the field of neurology and Alzheimer’s research, is set to join a distinguished group of neuroscientists and academics as a speaker at the USC-Sponsored Forum on Age-Related Diseases. This eagerly anticipated event aims to delve into the latest…
-
NeuroSense | Reporting Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
NASDAQ: NRSN Introduction NeuroSense, a groundbreaking biopharmaceutical company, is set to release the highly anticipated topline results of its Phase 2b clinical trial for ALS (Amyotrophic Lateral Sclerosis) on December 5, 2023. This milestone event marks a significant step forward in the search for new treatment options for this devastating disease. In this article, we…
-
Neurocrine Biosciences | Hosting Analyst Day on December 5, 2023
NASDAQ: $NBIX Neurocrine Biosciences to Host Analyst Day on December 5, 2023 Have you heard the news? Neurocrine Biosciences, a leading biopharmaceutical company, is set to host an Analyst Day on December 5, 2023. This highly anticipated event will bring together analysts, investors, and industry experts to explore Neurocrine Biosciences’ latest developments and future prospects.…
-
Intensity Therapeutics | Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
NASDAQ: INTS Intensity Therapeutics, a biotechnology company dedicated to developing innovative cancer therapies, has been selected to present at the prestigious Spotlight Oral Presentations. This recognition highlights the immense potential of the company’s scientific breakthroughs and further establishes its position as a leader in the field of oncology research. The selection also underscores the intelligence…